1. Home
  2. LMB vs MESO Comparison

LMB vs MESO Comparison

Compare LMB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LMB
  • MESO
  • Stock Information
  • Founded
  • LMB 1901
  • MESO 2004
  • Country
  • LMB United States
  • MESO Australia
  • Employees
  • LMB N/A
  • MESO N/A
  • Industry
  • LMB Engineering & Construction
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LMB Consumer Discretionary
  • MESO Health Care
  • Exchange
  • LMB Nasdaq
  • MESO Nasdaq
  • Market Cap
  • LMB 1.2B
  • MESO 1.2B
  • IPO Year
  • LMB 2014
  • MESO N/A
  • Fundamental
  • Price
  • LMB $89.76
  • MESO $14.63
  • Analyst Decision
  • LMB Strong Buy
  • MESO Strong Buy
  • Analyst Count
  • LMB 2
  • MESO 4
  • Target Price
  • LMB $106.50
  • MESO $13.50
  • AVG Volume (30 Days)
  • LMB 119.6K
  • MESO 552.8K
  • Earning Date
  • LMB 11-05-2024
  • MESO 08-28-2024
  • Dividend Yield
  • LMB N/A
  • MESO N/A
  • EPS Growth
  • LMB 29.01
  • MESO N/A
  • EPS
  • LMB 2.18
  • MESO N/A
  • Revenue
  • LMB $517,822,000.00
  • MESO $5,902,000.00
  • Revenue This Year
  • LMB $2.05
  • MESO $66.05
  • Revenue Next Year
  • LMB $12.13
  • MESO $348.27
  • P/E Ratio
  • LMB $41.21
  • MESO N/A
  • Revenue Growth
  • LMB 0.13
  • MESO N/A
  • 52 Week Low
  • LMB $35.24
  • MESO $1.61
  • 52 Week High
  • LMB $107.00
  • MESO $19.15
  • Technical
  • Relative Strength Index (RSI)
  • LMB 44.38
  • MESO 64.37
  • Support Level
  • LMB $84.59
  • MESO $12.20
  • Resistance Level
  • LMB $97.47
  • MESO $19.15
  • Average True Range (ATR)
  • LMB 4.61
  • MESO 0.98
  • MACD
  • LMB -1.71
  • MESO 0.37
  • Stochastic Oscillator
  • LMB 26.27
  • MESO 48.93

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: